The first part of the paper deals with the relationship between two inhibiting factors of the complex enzyme cascade regulating fibrinolysis, namely plasminogen activator inhibitor type-1 (PAT-1) and lipoprotein(a) (Lp(a)).Blood concentrations of Lp(a), PAI-1 antigen (PAI-1 AG) and activity (PAT-1 AT), and the main parameters of lipo- and glyco-metabolic balance were studied in 80 type II diabetic patients. Roughly hyperbolic patterns have been found between PAI-1 and Lp(a). Negative statistically significant linear correlation can be elicited when Log PAI-1 AG and Log PAT-I AT values are plotted versus Lp(a) values, the first one being particularly tight. These findings suggest a nearly on/off control of the two parameters, limiting the risk of hypofibrinolysis. The second part of the paper was aimed at verifying this hypothesis. A group of 30 diabetic patients were treated for 3 months with metformin, an antidiabetic biguanide compound which has been reported to reduce PAT-1 levels both in diabetic and in non-diabetic patients. Metformin significantly reduced PAI-1 AG and PAT-1 AT but did not influence plasma Lp(a) levels. A clear linear correlation between the basal Lp(a) values and the changes in PAI-1 AG levels was found. An even tighter correlation was elicited between the decrease in PAI-1, and PAI-1 pretreatment values.
- Non-insulin-dependent diabetes mellitus
- Plasminogen activator inhibitor type 1
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism